相关实验视频
Updated: Jan 15, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
903
抗肥胖药物 (纳尔特雷克森/布鲁) 在肥胖管理中:单中心早期经验
Siow Foon Tan1, Firdaus Mukhtar2,3, Ooi Chuan Ng4,3
1Pelabuhan Klang Primary Care Clinic, Pelabuhan Klang, Selangor, Malaysia.
The Malaysian journal of medical sciences : MJMS
|October 13, 2025
概括
纳尔特雷克松/布普罗皮昂在12周内显示出减肥和减少食欲的有效性. 早期的结果表明,它可能在肥胖管理中发挥作用,尽管需要进一步的研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 纳尔特雷/布普罗是马来西亚新批准的用于治疗肥胖症的药物.
- 关于其在马来西亚的实际有效性和患者结果的数据有限.
研究的目的:
- 在肥胖患者中评估纳尔特雷/布普罗12周的治疗结果.
- 评估药物的减肥,副作用和抗渴望作用.
主要方法:
- 在一个单一的代谢和肥胖诊所进行了前性观察试点研究.
- 在12周内收集了人口统计,并发症,体重,BMI,副作用和渴望减少的数据.
主要成果:
- 包括18名患者;14人完成了12周.
- 平均体重减轻量为2.11公斤 (2%的总体重).
- 纳尔特雷/布普罗有效地减少了75%的患者的食欲,常见的副作用包括头和恶心.
结论:
- 纳尔特雷克森/布普罗在肥胖管理方面表现出早期的前景,特别是在有渴望症状的患者中.
- 需要对更大的队列进行进一步的调查和更长的随访,以证实这些发现.
相关概念视频
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
246
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
246
Drug Dosing: Obese Patients
222
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
222
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
166
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
166
Antidepressant Drugs: MAOIs and Other Agents
823
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
823
Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
Drugs for Treatment of Constipation-Predominant IBS
717
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
717

